| 摘要 |
Compounds that may be used for the treatment or prevention of a condition associated with T-cell proliferation or that is mediated by pro-inflammatory cytokines are of formula (I): wherein R<subCompounds that may be used for the treatment or prevention of a condition associated with T-cell proliferation or that is mediated by pro-inflammatory cytokines are of formula (I): wherein R<SUB>1</SUB> is CHR<SUB>4</SUB>-OR<SUB>5</SUB> or CHR<SUB>4</SUB>-SR<SUB>5</SUB>, or aryl or heteroaryl optionally substituted with one or more groups R<SUB>6</SUB>; R<SUB>2</SUB> is alkyl or is part of a ring with R<SUB>3</SUB>; R<SUB>3</SUB> is H, alkyl or CH<SUB>2</SUB> (when forming part of a ring with R<SUB>2</SUB>); R<SUB>4</SUB> is H or alkyl or is part of a ring with R<SUB>5</SUB>; R<SUB>5</SUB> is aryl or heteroaryl optionally substituted with R<SUB>7</SUB>; each R<SUB>6</SUB> is independently alkyl, CF<SUB>3</SUB>, OH, Oalkyl, OCOalkyl, CONH<SUB>2</SUB>, CN, halogen, NH<SUB>2</SUB>, NO<SUB>2</SUB>, NHCHO, NHCONH<SUB>2</SUB>, NHSO<SUB>2</SUB>alkyl, CONH<SUB>2</SUB>, SOMe, SO<SUB>2</SUB>NH<SUB>2</SUB>, Salkyl, CH<SUB>2</SUB>SO<SUB>2</SUB>alkyl or OCONalkyl<SUB>2</SUB>; R<SUB>7</SUB> is R<SUB>8</SUB> or (CH<SUB>2</SUB>)<SUB>n</SUB>OR<SUB>8</SUB>, R<SUB>9</SUB>, CF<SUB>3</SUB>, OH, OR<SUB>9</SUB>, OCOR<SUB>9</SUB>, COR<SUB>9</SUB>, COOR<SUB>9</SUB>, CONH<SUB>2</SUB>, CH<SUB>2</SUB>CONH<SUB>2</SUB>, CN, halogen, NH<SUB>2</SUB>, NO<SUB>2</SUB>, NHCHO, NHCONH<SUB>2</SUB>, NHCONHR<SUB>7</SUB>, NHCON(R<SUB>9</SUB>)<SUB>2</SUB>, NHCOR<SUB>9</SUB>, NHCOaryl, NHSO<SUB>2</SUB>Me, CONH<SUB>2</SUB>, SMe, SOMe or SO<SUB>2</SUB>NH<SUB>2</SUB>; R<SUB>8</SUB> is (CH<SUB>2</SUB>)<SUB>n</SUB>OR<SUB>9</SUB>, (CH)<SUB>n</SUB>OR<SUB>9</SUB>, (CH<SUB>2</SUB>)<SUB>n</SUB>COOR<SUB>9</SUB> or (CH<SUB>2</SUB>)<SUB>n</SUB>COaryl; R<SUB>9</SUB> is alkyl or cycloalkyl; and n is 1 to 4; or a salt thereof, including clenbuterol and atenolol. |
